|
Dec 4
|
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
|
|
Dec 4
|
After losing 5.2% in the past year, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) institutional owners must be relieved by the recent gain
|
|
Dec 2
|
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023)
|
|
Nov 30
|
Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering
|
|
Nov 29
|
Xenon Pharmaceuticals Announces Proposed Public Offering
|
|
Nov 28
|
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
|
|
Nov 27
|
The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring
|
|
Nov 27
|
UPDATE 1-Canada's Xenon Pharma's depression drug fails to meet main goal in study
|
|
Nov 27
|
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD)
|
|
Nov 27
|
Xenon drug misses main goal of depression study
|
|
Nov 9
|
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Earnings Call Transcript
|
|
Nov 9
|
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
|
|
Nov 8
|
Xenon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
|
|
Aug 9
|
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 9
|
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
|
|
Aug 9
|
Companies Like Xenon Pharmaceuticals (NASDAQ:XENE) Are In A Position To Invest In Growth
|
|
Aug 8
|
Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
|